Your browser is no longer supported. Please, upgrade your browser.
JAGX Jaguar Health, Inc. daily Stock Chart
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-5.21 Insider Own17.39% Shs Outstand25.16M Perf Week-20.95%
Market Cap5.96M Forward P/E- EPS next Y- Insider Trans-6.10% Shs Float20.33M Perf Month-47.33%
Income-40.70M PEG- EPS next Q- Inst Own13.60% Short Float3.24% Perf Quarter-57.60%
Sales4.40M P/S1.36 EPS this Y62.40% Inst Trans20.75% Short Ratio0.32 Perf Half Y-85.19%
Book/sh0.86 P/B0.28 EPS next Y- ROA-87.40% Target Price1.25 Perf Year-87.94%
Cash/sh0.03 P/C8.52 EPS next 5Y40.00% ROE-260.00% 52W Range0.28 - 6.60 Perf YTD-88.70%
Dividend- P/FCF- EPS past 5Y- ROI-63.90% 52W High-96.41% Beta0.45
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin44.00% 52W Low-16.40% ATR0.04
Employees17 Current Ratio0.50 Sales Q/Q0.00% Oper. Margin- RSI (14)19.94 Volatility17.26% 11.75%
OptionableNo Debt/Eq1.58 EPS Q/Q-147.90% Profit Margin- Rel Volume0.66 Prev Close0.29
ShortableYes LT Debt/Eq1.04 Earnings- Payout- Avg Volume2.03M Price0.24
Recom2.00 SMA20-40.07% SMA50-47.92% SMA200-83.53% Volume1,330,226 Change-19.66%
Jul-11-17Initiated Rodman & Renshaw Buy $2
Dec-06-18 08:00AM  Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer ACCESSWIRE -14.23%
Nov-14-18 08:05PM  Jaguar Health, Inc. Reports Third-Quarter 2018 Results ACCESSWIRE
Nov-13-18 08:00AM  Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th ACCESSWIRE
Oct-29-18 09:00AM  The Brilliance Behind a Global Operator of Crypto Exchanges BitMax: Understanding the Trans-Fee Mining Model ACCESSWIRE
09:00AM  Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th ACCESSWIRE
Oct-24-18 09:00AM  Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida ACCESSWIRE -9.86%
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-02-18 06:00AM  Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering ACCESSWIRE -24.18%
Sep-26-18 10:30AM  These Biotech and Cannabis Stocks Are Skyrocketing ACCESSWIRE -36.90%
08:00AM  Today's Research Reports on Trending Tickers: Jaguar Health and TG Therapeutics ACCESSWIRE
Sep-25-18 02:40PM  Jaguar Health's stock triples after licensing deal, has been halted 13 times for volatility MarketWatch +158.46%
Sep-24-18 04:36PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership GlobeNewswire
04:30PM  Knight Therapeutics and Jaguar Health Announce Strategic Partnership ACCESSWIRE
Aug-27-18 07:55AM  Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jul-25-18 08:00AM  RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire
Jul-24-18 09:00AM  New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time ACCESSWIRE
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE -6.78%
Jul-16-18 09:00AM  Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference ACCESSWIRE -10.95%
Jul-12-18 09:00AM  Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates ACCESSWIRE +8.82%
Jun-28-18 09:00AM  RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi® GlobeNewswire +5.00%
09:00AM  Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product ACCESSWIRE
Jun-25-18 07:45AM  Research Report Identifies Glu Mobile, Reliance Steel & Aluminum, FedEx, Jaguar Animal Health, Box, and VirnetX Holding with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -8.81%
Jun-20-18 09:00AM  Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors ACCESSWIRE
Jun-18-18 09:00AM  Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors ACCESSWIRE
Jun-15-18 07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-12-18 09:00AM  Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients ACCESSWIRE
Jun-04-18 08:10AM  Today's Research Reports on Stocks to Watch: Co-Diagnostics and Jaguar Health ACCESSWIRE +9.56%
Jun-03-18 08:34AM  Is Jaguar Health Incs (NASDAQ:JAGX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Jun-01-18 09:00AM  Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split ACCESSWIRE -8.84%
May-29-18 09:00AM  Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals ACCESSWIRE
May-18-18 05:24PM  Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders ACCESSWIRE
May-15-18 11:15AM  Jaguar Health Inc (NASDAQ:JAGX): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
09:00AM  ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea ACCESSWIRE
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-07-18 08:15AM  Research Report Identifies Jaguar Animal Health, Dollar Tree, WPX Energy, Abaxis, Lear, and Baker Hughes with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-19-18 09:00AM  Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea ACCESSWIRE
Apr-10-18 09:00AM  Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi ACCESSWIRE +6.97%
Apr-09-18 09:00AM  Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV ACCESSWIRE
Apr-02-18 09:00AM  Jaguar Health Appoints Jonathan B. Siegel to Board of Directors ACCESSWIRE
Mar-26-18 06:30AM  Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi ACCESSWIRE
Mar-13-18 07:02PM  Why Jaguar Health Incs (NASDAQ:JAGX) CEO Pay Matters To You Simply Wall St. -9.32%
03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc. Business Wire
08:05AM  Jaguar Health, Pipeline Review, Analyst Ratings, Milestones ACCESSWIRE
Mar-09-18 08:10AM  Todays Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health ACCESSWIRE -31.05%
Mar-08-18 09:00AM  FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs ACCESSWIRE +131.00%
Mar-05-18 08:10AM  Report: Developing Opportunities within TripAdvisor, Glu Mobile, KeyCorp, SMART SAND INC, Jaguar Animal Health, and Cleveland-Cliffs Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-02-18 09:00AM  Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program ACCESSWIRE
Mar-01-18 01:23PM  How Financially Strong Is Jaguar Health Inc (NASDAQ:JAGX)? Simply Wall St.
Jan-22-18 04:00PM  Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (AugustDecember 2017) Business Wire
Jan-18-18 09:00AM  Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results Business Wire +21.13%
08:30AM  Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim Business Wire
Jan-06-18 11:50AM  Jaguar Health Inc (NASDAQ:JAGX): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
Jan-01-18 09:19AM  Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 Capital Cube
Dec-26-17 11:00AM  WallStreet Research(TM) Announces Release of Corporate Profile Coverage on Jaguar Health, Inc. (NASDAQ: JAGX) ACCESSWIRE
Dec-14-17 10:09AM  Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguars Personalized, Premium Product for Total Gut Health and Wellness in Horses Business Wire +5.52%
Dec-12-17 09:00AM  New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence Business Wire
Dec-01-17 04:10PM  Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 Business Wire
09:00AM  Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline Business Wire
Nov-30-17 02:05PM  What You Must Know About Jaguar Health Incs (JAGX) Financial Strength Simply Wall St.
Nov-27-17 09:00AM  Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC Business Wire
Nov-20-17 09:36AM  Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals Business Wire
Nov-16-17 09:15AM  Jaguar Health Presenting Neonorm Calf at Western Organic Dairy Producers Alliance Conference Business Wire -5.38%
Nov-15-17 09:02AM  Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napos FDA-Approved Human Prescription Drug Business Wire -6.88%
Nov-14-17 05:54PM  Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Healths Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million Business Wire
03:27PM  Todays Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time Business Wire
06:09AM  Is Jaguar Health Inc (JAGX) A Healthcare Industry Laggard Or Leader? Simply Wall St.
Nov-09-17 04:12PM  Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time Business Wire
Nov-08-17 07:30AM  Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi Business Wire +13.85%
Nov-07-17 09:00AM  Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals Business Wire -6.23%
Nov-01-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napos FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug Business Wire
08:00AM  Investor Expectations to Drive Momentum within VWR, The Michaels Companies, KalVista Pharmaceuticals, PACCAR, Jaguar Health, and CPI Card Group Discovering Underlying Factors of Influence GlobeNewswire
Oct-26-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Launches National Keep Your Pants On Unless You Dont Want To Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS Business Wire
Oct-20-17 03:56PM  Why Jaguar Health Incs (JAGX) Ownership Structure Is Important Simply Wall St.
Oct-19-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napos FDA-approved Human Prescription Drug Business Wire
Oct-18-17 09:04AM  Napo Pharmaceuticals Endorses Prevention Access Campaigns U=U Consensus Statement for People Living With HIV/AIDS (PLWHA) Business Wire
Oct-04-17 08:00AM  Jaguar Health, Product Pipeline Review and Outlook ACCESSWIRE -6.56%
Oct-02-17 08:00AM  Today's Research Reports on Trending Tickers: Synergy Pharmaceuticals and Jaguar Health ACCESSWIRE +19.25%
Sep-29-17 01:24PM  Jaguar Health Prices $4.25 Million Public Offering of Common Stock Business Wire -50.22%
Sep-28-17 09:13AM  Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napos FDA-Approved Human Drug, to Support Upcoming National Sample Campaign Business Wire
Sep-25-17 09:00AM  Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguars Global Commercial Control of Mytesi (Crofelemer), Jaguars FDA-Approved Human Drug Business Wire +18.74%
Sep-20-17 09:00AM  FDA Indicates That Jaguars Canalevia Drug Product Candidate Qualifies as Minor Use for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication Business Wire
Sep-18-17 10:07AM  Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors Business Wire
08:16AM  Jaguar Health Announces Proposed Public Offering of Common Stock Business Wire
Sep-15-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets Business Wire -16.60%
Sep-12-17 12:16PM  New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients Business Wire +6.82%
Aug-25-17 10:48AM  Jaguar Health, Inc. :JAGX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube -18.37%
Aug-16-17 09:00AM  Jaguar Health Company Name Now Updated on Post-Merger Business Wire -7.80%
Aug-07-17 09:00AM  Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome Business Wire
Aug-04-17 05:00PM  Monteverde & Associates PC Files Class Action Lawsuit on Behalf of Shareholders of Jaguar Animal Health, Inc. in the Northern District of California PR Newswire +5.50%
Jul-31-17 07:33PM  The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective Business Wire -21.68%
Jul-27-17 08:08PM  Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger Business Wire
Jul-24-17 09:00AM  New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment Business Wire
Jul-18-17 09:00AM  Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal Business Wire
Jul-06-17 05:38PM  Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc. Business Wire
Jun-30-17 01:21PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Jaguar Animal Health, Inc. - JAGX PR Newswire
Jun-27-17 09:00AM  Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science Business Wire
Jun-14-17 09:00AM  Jaguar Animal Healths Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle Business Wire
Jun-07-17 09:00AM  Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf Business Wire
Jun-05-17 09:00AM  Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs Business Wire
Jun-02-17 09:52AM  Jaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Siegel Jonathan B.DirectorOct 04Buy0.6025,00015,00040,000Oct 05 04:39 PM
Nantucket Investments Ltd10% OwnerSep 25Sale1.83325,615595,8750Oct 24 09:43 AM
Siegel Jonathan B.DirectorJul 18Buy1.105,0005,47614,732Jul 20 05:00 PM
CONTE LISA ACEO and PresidentJul 18Buy1.111,5001,6697,500Jul 18 05:00 PM
Siegel Jonathan B.DirectorJul 17Buy1.192,2322,6569,732Jul 18 05:00 PM
Siegel Jonathan B.DirectorJul 16Buy1.367,50010,1909,732Jul 18 05:00 PM